J. Scheele

1.8k total citations
32 papers, 197 citations indexed

About

J. Scheele is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, J. Scheele has authored 32 papers receiving a total of 197 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 5 papers in Genetics. Recurrent topics in J. Scheele's work include Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Gastric Cancer Management and Outcomes (8 papers). J. Scheele is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Gastric Cancer Management and Outcomes (8 papers). J. Scheele collaborates with scholars based in Germany, United States and Japan. J. Scheele's co-authors include Rolf Bruns, Enriqueta Felip, Paul K. Paik, Hiroshi Sakai, Jyoti D. Patel, Leora Horn, Rémi Veillon, Frank Griesinger, Tomohiro Sakamoto and Jan P. van Meerbeeck and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

J. Scheele

30 papers receiving 194 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Scheele Germany 7 146 98 53 53 42 32 197
Sabine Glaser Switzerland 5 211 1.4× 137 1.4× 104 2.0× 50 0.9× 38 0.9× 8 296
Sylvie Le Mouhaër Switzerland 9 219 1.5× 134 1.4× 100 1.9× 55 1.0× 36 0.9× 17 267
Karin Berghoff Germany 8 123 0.8× 134 1.4× 120 2.3× 69 1.3× 43 1.0× 28 277
S. Mancarella Italy 10 172 1.2× 274 2.8× 38 0.7× 42 0.8× 29 0.7× 24 334
Krassimir Koynov Bulgaria 6 114 0.8× 195 2.0× 47 0.9× 35 0.7× 15 0.4× 12 242
Uriel Bohn Spain 9 85 0.6× 144 1.5× 33 0.6× 25 0.5× 23 0.5× 16 253
Olçun Ümit Ünal Türkiye 10 98 0.7× 132 1.3× 52 1.0× 20 0.4× 21 0.5× 40 235
C. Valsuani Italy 9 105 0.7× 200 2.0× 49 0.9× 63 1.2× 31 0.7× 16 248
Thomas Göhler Germany 10 67 0.5× 132 1.3× 39 0.7× 46 0.9× 28 0.7× 34 225
Barbara Schacher Engstler Switzerland 3 102 0.7× 88 0.9× 124 2.3× 41 0.8× 25 0.6× 4 248

Countries citing papers authored by J. Scheele

Since Specialization
Citations

This map shows the geographic impact of J. Scheele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Scheele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Scheele more than expected).

Fields of papers citing papers by J. Scheele

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Scheele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Scheele. The network helps show where J. Scheele may publish in the future.

Co-authorship network of co-authors of J. Scheele

This figure shows the co-authorship network connecting the top 25 collaborators of J. Scheele. A scholar is included among the top collaborators of J. Scheele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Scheele. J. Scheele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Yi‐Long, Ying Cheng, Jianfeng Zhou, et al.. (2019). MA09.09 Long-Term Outcomes to Tepotinib Plus Gefitinib in Patients with EGFR-Mutant NSCLC and MET Dysregulation: 18-Month Follow-Up. Journal of Thoracic Oncology. 14(10). S284–S284. 7 indexed citations
2.
Paik, Paul K., Alexis B. Cortot, Enriqueta Felip, et al.. (2019). A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study. Annals of Oncology. 30. ii66–ii66. 4 indexed citations
3.
Park, K., Enriqueta Felip, Rémi Veillon, et al.. (2019). Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study. Annals of Oncology. 30. ix22–ix23. 6 indexed citations
4.
Yamazaki, Kentaro, Baek‐Yeol Ryoo, Toshihiko Doi, et al.. (2019). Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours. Annals of Oncology. 30. ix26–ix26. 3 indexed citations
5.
Wu, Yi‐Long, Jianya Zhou, Shun Lü, et al.. (2018). Tepotinib + gefitinib (TEP+GEF) in MET+/epidermal growth factor receptor (EGFR)-mutant non-small lung cancer (NSCLC): Phase II data. Annals of Oncology. 29. ix159–ix159. 2 indexed citations
6.
Paik, Paul K., Hiroshi Sakai, Rolf Bruns, et al.. (2018). Tepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14 skipping mutations (METex14+) and MET amplification (METamp); A phase II trial in progress. Annals of Oncology. 29. ix169–ix169. 3 indexed citations
7.
Jurczak, Wojciech, Simon Rule, William Townsend, et al.. (2018). A Phase I/II, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies. Blood. 132(Supplement 1). 4161–4161. 3 indexed citations
8.
Felip, Enriqueta, Rémi Veillon, Santiago Viteri, et al.. (2018). Abstract A097: Phase II trial of the c-Met inhibitor tepotinib in patients with advanced non-small cell lung cancer harboring MET exon 14-skipping mutations. Molecular Cancer Therapeutics. 17(1_Supplement). A097–A097. 2 indexed citations
9.
Sakai, Hiroshi, Enriqueta Felip, Alexis B. Cortot, et al.. (2018). Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data. Annals of Oncology. 29. ix152–ix152. 1 indexed citations
10.
Jurczak, Wojciech, Simon Rule, William Townsend, et al.. (2018). Phase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies. Annals of Oncology. 29. viii362–viii363. 3 indexed citations
11.
Zhou, Jin, Sheng-Feng Lu, Y. Zhang, et al.. (2018). Phase II study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC). Annals of Oncology. 29. viii493–viii493. 21 indexed citations
12.
Jurczak, Wojciech, Simon Rule, William Townsend, et al.. (2017). First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes. Blood. 130. 2778–2778. 3 indexed citations
13.
Wu, Yi‐Long, Ross A. Soo, Dong‐Wan Kim, et al.. (2017). Phase Ib study of tepotinib in EGFR-mutant/c-Met-positive NSCLC: Final data and long-term responders.. Journal of Clinical Oncology. 35(15_suppl). 8547–8547.
14.
Qin, Shukui, Tae‐You Kim, Ho Yeong Lim, et al.. (2017). Phase Ib trial of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC): Final data including long-term outcomes.. Journal of Clinical Oncology. 35(15_suppl). 4087–4087. 3 indexed citations
15.
Rule, Simon, et al.. (2017). Phase I/II, first in human trial of the Bruton’s tyrosine kinase inhibitor (BTKi) M7583 in patients with B cell malignancies.. Journal of Clinical Oncology. 35(15_suppl). e14101–e14101. 2 indexed citations
16.
Täubert, Helge, J. Scheele, Claudia Rudroff, et al.. (2002). Association of p53 mutations, microvessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastases. International Journal of Oncology. 21(2). 243–9. 16 indexed citations
17.
Scheele, J., et al.. (2002). Differentiation of positive autofluorescence bronchoscopy findings by comparative genomic hybridization. Oncology Reports. 9(4). 697–701. 13 indexed citations
18.
Scheele, J., R. Stangl, A. Altendorf-Hofmann, & Gall Fp. (1991). [Regional chemotherapy of diffuse liver metastases of colorectal cancer].. PubMed. 116(21). 1215–35. 3 indexed citations
19.
Altendorf-Hofmann, A. & J. Scheele. (1990). [Differential after care for early detection of recurrence: from the surgical viewpoint].. PubMed. 231–8. 1 indexed citations
20.
Scheele, J., et al.. (1952). [Therapy and prophylaxis of thromboembolism with venostasin].. PubMed. 20. 693–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sabine Glaser Breakdown of academic impact, for papers by Sylvie Le Mouhaër Breakdown of academic impact, for papers by Karin Berghoff Breakdown of academic impact, for papers by S. Mancarella Breakdown of academic impact, for papers by Krassimir Koynov Breakdown of academic impact, for papers by Uriel Bohn Breakdown of academic impact, for papers by Olçun Ümit Ünal Breakdown of academic impact, for papers by C. Valsuani Breakdown of academic impact, for papers by Thomas Göhler Breakdown of academic impact, for papers by Barbara Schacher Engstler
Rankless by CCL
2026